Multithread effectively and personalize outreach to convert deals faster
Elevate social presence and drive business growth from social media
Identify and prioritize high-intent leads, and improve sales effectiveness
Find and connect with ICP attendees, and improve event outcomes
OncoResponse is a clinical-stage immuno-oncology company at the forefront of cancer therapy development. By uniquely harnessing the power of the human immune system, OncoResponse identifies potent antibodies from "Elite Responders" – patients who have demonstrated exceptional and durable responses to cancer immunotherapies. This innovative approach allows the company to discover and develop novel therapeutics aimed at transforming cancer treatment paradigms and improving patient outcomes across various oncology indications. Their platform focuses on mining the human immune repertoire to unlock next-generation treatments.
Serves as the central hub for research and development, clinical program management, corporate operations, and strategic leadership.
Located in a modern life sciences building in Seattle's Eastlake neighborhood, offering state-of-the-art laboratory and office facilities conducive to biotech innovation.
A dynamic, collaborative, and science-driven environment focused on innovation in oncology. Employees are mission-oriented, dedicated to advancing cancer treatments for patients.
The Seattle location provides access to a rich biotech ecosystem, a highly skilled talent pool, and proximity to leading research institutions, crucial for OncoResponse's pioneering work.
While headquartered in Seattle, OncoResponse's operations have a global reach, particularly through its clinical trial activities which may be conducted in multiple countries. The company collaborates with international research institutions and partners to advance its pipeline of novel cancer therapeutics, aiming to address unmet medical needs for patients worldwide.
188 East Blaine Street, Suite 450
Seattle
WA
USA
No additional office locations available.
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, OncoResponse' leadership includes:
OncoResponse has been backed by several prominent investors over the years, including:
OncoResponse has recently made key appointments to its Board of Directors to guide its strategic growth. No operational executive departures have been publicly announced in the last 12 months. A key Vice President role was filled approximately 13 months ago.
Discover the tools OncoResponse uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
OncoResponse likely utilizes a common corporate email format. Based on patterns observed in similar biotech companies and general corporate practices, the most probable format is the first initial followed by the last name.
f[last]@oncoresponse.com
Format
jdoe@oncoresponse.com
Example
85%
Success rate
Business Wire • May 16, 2024
OncoResponse announced the appointment of Jon Wigginton, M.D., to its Board of Directors. Dr. Wigginton brings extensive experience in oncology drug development and immuno-oncology to the company....more
Business Wire • April 8, 2024
OncoResponse shared promising preclinical data for its lead candidate OR2805 at the American Association for Cancer Research (AACR) Annual Meeting 2024. The data highlighted OR2805's potential in treating various cancers by targeting LILRB2, an immune checkpoint receptor....more
Business Wire • December 12, 2023
OncoResponse announced that the first patient has been dosed in its Phase 1/2 clinical trial evaluating OR2805. OR2805 is a LILRB2 antagonist antibody being studied in patients with advanced solid tumors....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including OncoResponse, are just a search away.